RFA-AI-24-068: New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 31, 2025.
From the official notice on Grants.gov, last changed October 15, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21 / R33
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$237,751
- Typical project length2 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under RFA-AI-24-068 were run by National Institute of Allergy and Infectious Diseases (NIAID, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-24-068 in the NIH Guide.
Key dates
| Posted | October 15, 2024 |
|---|---|
| Deadline | January 31, 2025 |
| Archived by Grants.gov | March 8, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to stimulate the development of new treatments for genital herpes that suppress shedding and lesion formation and reduce transmission. This NOFO invites applications that propose research into a broad range of therapeutic approaches, including but not limited to development of new or improved antivirals, monoclonal antibodies, therapeutic vaccines, and gene editing technologies for treatment of patients living with genital herpes. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase is not guaranteed and will depend on the successful completion of milestones.
Funded under RFA-AI-24-068 so far
NIH funded 7 projects under RFA-AI-24-068 in fiscal 2026, at 6 institutions. The median yearly award was $237,751.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Targeting Evasion Factors: Discovery of novel antibodies for durable suppression of HSV reactivation | Dartmouth College | 2026 | $215,758 |
| HSV alkaline nuclease as a target for antiviral therapy | University of Connecticut Sch of Med/DNT | 2026 | $263,375 |
| AAV-delivered meganucleases for durable control of genital HSV disease | Fred Hutchinson Cancer Center | 2026 | $232,558 |
| Harnessing in-tissue antibodies for therapeutic HSV control | Fred Hutchinson Cancer Center | 2026 | $238,899 |
| Herpes Simplex Immunotherapeutic Targeting CD8 T cells | University of Washington | 2026 | $256,074 |
| CRISPR-based in vivo attenuation of HSV to improve immune control of genital herpes infection | Temple Univ of the Commonwealth | 2026 | $237,751 |
| Human ADCC-Mediating Monoclonal Antibodies for Treatment and Prevention of HSV | Albert Einstein College of Medicine | 2026 | $231,000 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-24-068 still open?
No. It closed on January 31, 2025.
Who can apply for New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)?
Closed January 31, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AI-24-068?
NIH RePORTER lists 7 projects funded under RFA-AI-24-068 in fiscal 2026, at 6 institutions. The most were at Fred Hutchinson Cancer Center, Dartmouth College, University of Connecticut Sch of Med/DNT.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)